Category HR+ Breast Cancer

Palbociclib and Fulvestrant for Advanced Breast Cancer: Benefits, Survival Data and Side Effects

Palbociclib and Fulvestrant Treatment calender

Medically reviewed by: Dr. Salma Mamdouh Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center Published: July 2026 · Last medically reviewed: July 2026 · This page provides general education about a specific treatment combination. It does not replace individualized advice from…

CDK4/6 Pathway Dysregulation in Oncology: Molecular Drivers and Targeted Inhibitor Protocols

Mechanism-of-action-of-CDK4-6-inhibitors-Inhibition-of-G1-S-checkpoint | CDK4/6 Pathway

Protocol Summary Receiving an advanced oncology diagnosis necessitates an immediate transition from generalized anatomical staging to precise molecular and genomic profiling. In contemporary clinical oncology, the standard of care dictates that malignancies are evaluated and treated based on their specific,…

AKT Mutation Alterations in Oncology: Molecular Drivers and Targeted Inhibitor Protocols

Schematic-diagram-of-PI3K-Akt-mTOR-pathway-AKT Mutation

Educational Overview Receiving an advanced cancer diagnosis immediately necessitates a transition from generalized anatomical staging to precise molecular profiling. In modern oncology, the standard of care dictates that malignancies are treated based on their specific genetic drivers. Among the most…

Trending now

KRAS G12C Mutation involvement in non-small cell lung cancer. The Diagram shows the historical data of this mutation.
KRAS G12C Mutation in Advanced NSCLC: Targeted Therapies and Clinical Management
BRAF Mutation Data Graph
Clinical Guide to the BRAF Mutation and Targeted Therapy
CML Treatment with different molecules
CML Treatment: Imatinib vs Dasatinib vs Ponatinib vs Asciminib
How Receptor Tyrosine kinase inhibitor works in non-small cell lung cancer
NSCLC Targeted Therapies: Biomarker Profiling and Precision Oncology Protocols